View:
United States securities and exchange commission logo
February 3, 2023
Frederic Guerard, Pharm.D.
President and Chief Executive Officer
Graybug Vision, Inc.
203 Redwood Shores Parkway, Suite 620
Redwood City, CA 94065
Re: Graybug Vision,
Inc.
Amendment No. 2 to
Preliminary Proxy Statement on Schedule 14A
Filed January 31,
2023
File No. 001-39538
Dear Frederic Guerard:
We have reviewed your filing and have the following comments. In
some of our
comments, we may ask you to provide us with information so we may better
understand your
disclosure.
Please respond to these comments within ten business days by
providing the requested
information or advise us as soon as possible when you will respond. If
you do not believe our
comments apply to your facts and circumstances, please tell us why in
your response.
After reviewing your
response to these comments, we may have additional comments.
Amendment No. 2 to Preliminary Proxy Statement on Schedule 14A filed
January 31, 2023
Graybug's Reasons for the Merger Recommendations of the Graybug Board,
page 104
1. We note your response
to comment 1. Please revise to disclose how the board, in
recommending the
business combination, considered the fact that the selected public
companies analysis and
selected IPOs analysis did not take into consideration the number
of product candidates
each company was developing, the stage of clinical development of
each product candidate
for each indication, and the potential addressable market including
the expected dosing
period of Auxora.
Graybug Management Liquidation Analysis, page 122
2. We note your response
to comment 3 and reissue in part. Given that Piper Sandler
assumed a 25% chance of
success and that FDA approval is a yes or no decision, it
appears Piper Sandler
applied a probability of success adjustment that indicated it was
more probable that
Auxora would not be approved by the FDA and that it was more
Frederic Guerard, Pharm.D.
Graybug Vision, Inc.
February 3, 2023
Page 2
probable to not generate any revenues. Please revise to disclose how the
board took this
into consideration in recommending the business combination.
We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.
You may contact Ibolya Ignat at 202-551-3636 or Daniel Gordon at
202-551-3486 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Daniel Crawford at 202-551-7767 or Tim Buchmiller at 202-551-3635 with
any other
questions.
Sincerely,
FirstName LastNameFrederic Guerard, Pharm.D.
Division of
Corporation Finance
Comapany NameGraybug Vision, Inc.
Office of Life
Sciences
February 3, 2023 Page 2
cc: Julia Forbess, Esq.
FirstName LastName